Clovoxamine kinetics in an early clinical trial

Harrell E. Hurst, David R. Jones, Jesse H. Wright, Charles H. Jarboe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Elimination kinetics of the new antidepressant clovoxamine were determined in a preliminary clinical trial in 10 depressed patients. When final oral doses of 50 mg clovoxamine fumarate were given, the mean peak steady-state plasma concentration was about 60 nglml after 3 hr. Clovoxamine elimination proceeded by an apparent single-phasic, first-order decline with a mean t 1 2 of 9.5 ± 2.8 hr. One subject had an unusually long t 1 2 (31.5 hr) and had correspondingly high clovoxamine plasma concentrations. The mean apparent volume of distribution (Vd) calculated from oral dosage was 19.5 ± 6 l/kg, but one atypical subject had an apparent Vd of 96 llkg. The mean apparent oral clearance was 25.5 ± 12.5 ml/min/kg. These parameters should be of assistance in planning dosage regimens and monitoring therapeutic blood levels according to kinetic principles. Atypical clovoxamine kinetics can be associated with abnormally high or low blood levels and could therefore lead to variability in clinical response.

Original languageEnglish (US)
Pages (from-to)266-271
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume34
Issue number2
StatePublished - Aug 1983
Externally publishedYes

Fingerprint

Clinical Trials
Fumarates
Antidepressive Agents
clovoxamine
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hurst, H. E., Jones, D. R., Wright, J. H., & Jarboe, C. H. (1983). Clovoxamine kinetics in an early clinical trial. Clinical Pharmacology and Therapeutics, 34(2), 266-271.

Clovoxamine kinetics in an early clinical trial. / Hurst, Harrell E.; Jones, David R.; Wright, Jesse H.; Jarboe, Charles H.

In: Clinical Pharmacology and Therapeutics, Vol. 34, No. 2, 08.1983, p. 266-271.

Research output: Contribution to journalArticle

Hurst, HE, Jones, DR, Wright, JH & Jarboe, CH 1983, 'Clovoxamine kinetics in an early clinical trial', Clinical Pharmacology and Therapeutics, vol. 34, no. 2, pp. 266-271.
Hurst HE, Jones DR, Wright JH, Jarboe CH. Clovoxamine kinetics in an early clinical trial. Clinical Pharmacology and Therapeutics. 1983 Aug;34(2):266-271.
Hurst, Harrell E. ; Jones, David R. ; Wright, Jesse H. ; Jarboe, Charles H. / Clovoxamine kinetics in an early clinical trial. In: Clinical Pharmacology and Therapeutics. 1983 ; Vol. 34, No. 2. pp. 266-271.
@article{b0a310ac3f65464f9ae2c278967675fa,
title = "Clovoxamine kinetics in an early clinical trial",
abstract = "Elimination kinetics of the new antidepressant clovoxamine were determined in a preliminary clinical trial in 10 depressed patients. When final oral doses of 50 mg clovoxamine fumarate were given, the mean peak steady-state plasma concentration was about 60 nglml after 3 hr. Clovoxamine elimination proceeded by an apparent single-phasic, first-order decline with a mean t 1 2 of 9.5 ± 2.8 hr. One subject had an unusually long t 1 2 (31.5 hr) and had correspondingly high clovoxamine plasma concentrations. The mean apparent volume of distribution (Vd) calculated from oral dosage was 19.5 ± 6 l/kg, but one atypical subject had an apparent Vd of 96 llkg. The mean apparent oral clearance was 25.5 ± 12.5 ml/min/kg. These parameters should be of assistance in planning dosage regimens and monitoring therapeutic blood levels according to kinetic principles. Atypical clovoxamine kinetics can be associated with abnormally high or low blood levels and could therefore lead to variability in clinical response.",
author = "Hurst, {Harrell E.} and Jones, {David R.} and Wright, {Jesse H.} and Jarboe, {Charles H.}",
year = "1983",
month = "8",
language = "English (US)",
volume = "34",
pages = "266--271",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Clovoxamine kinetics in an early clinical trial

AU - Hurst, Harrell E.

AU - Jones, David R.

AU - Wright, Jesse H.

AU - Jarboe, Charles H.

PY - 1983/8

Y1 - 1983/8

N2 - Elimination kinetics of the new antidepressant clovoxamine were determined in a preliminary clinical trial in 10 depressed patients. When final oral doses of 50 mg clovoxamine fumarate were given, the mean peak steady-state plasma concentration was about 60 nglml after 3 hr. Clovoxamine elimination proceeded by an apparent single-phasic, first-order decline with a mean t 1 2 of 9.5 ± 2.8 hr. One subject had an unusually long t 1 2 (31.5 hr) and had correspondingly high clovoxamine plasma concentrations. The mean apparent volume of distribution (Vd) calculated from oral dosage was 19.5 ± 6 l/kg, but one atypical subject had an apparent Vd of 96 llkg. The mean apparent oral clearance was 25.5 ± 12.5 ml/min/kg. These parameters should be of assistance in planning dosage regimens and monitoring therapeutic blood levels according to kinetic principles. Atypical clovoxamine kinetics can be associated with abnormally high or low blood levels and could therefore lead to variability in clinical response.

AB - Elimination kinetics of the new antidepressant clovoxamine were determined in a preliminary clinical trial in 10 depressed patients. When final oral doses of 50 mg clovoxamine fumarate were given, the mean peak steady-state plasma concentration was about 60 nglml after 3 hr. Clovoxamine elimination proceeded by an apparent single-phasic, first-order decline with a mean t 1 2 of 9.5 ± 2.8 hr. One subject had an unusually long t 1 2 (31.5 hr) and had correspondingly high clovoxamine plasma concentrations. The mean apparent volume of distribution (Vd) calculated from oral dosage was 19.5 ± 6 l/kg, but one atypical subject had an apparent Vd of 96 llkg. The mean apparent oral clearance was 25.5 ± 12.5 ml/min/kg. These parameters should be of assistance in planning dosage regimens and monitoring therapeutic blood levels according to kinetic principles. Atypical clovoxamine kinetics can be associated with abnormally high or low blood levels and could therefore lead to variability in clinical response.

UR - http://www.scopus.com/inward/record.url?scp=0020574136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020574136&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 266

EP - 271

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -